Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With STEMI

Launched by AIN SHAMS UNIVERSITY · Aug 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a supplement called L-Carnitine on heart damage in patients who have experienced a type of heart attack known as STEMI. The main goal is to see if L-Carnitine can help reduce certain harmful markers in the blood that indicate heart injury after medical treatment called primary PCI, which is a procedure to open blocked arteries. The researchers will specifically look at markers related to oxidative stress and heart tissue damage.

To be eligible for this trial, participants need to be between 18 and 75 years old and have experienced a STEMI that is being treated with PCI. However, people who have had a recent heart attack, certain heart surgeries, or specific health issues like severe liver or kidney problems cannot participate. If you join the study, you will be monitored for your response to L-Carnitine and any side effects, helping researchers understand its potential benefits for heart recovery. The trial is not yet recruiting, so there’s time to learn more if you or a loved one might be interested.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Female or male aged \>18 and \< 75 years.
• • STEMI patients undergoing PCI.
• Exclusion Criteria:
• • Patients with a recent history of myocardial infarction (MI), a previous PCI, a previous coronary artery bypass graft, or any cardiac surgery.
• • A late presentation (\>12 h), unsuccessful primary PCI (residual stenosis \>50% in the culprit lesion after procedure),
• • Pretreatment with thrombolytic or glycoprotein IIb/IIIa inhibitor therapy before primary PCI,
• • Concurrent Infectious or active inflammatory disease,
• • Severe liver or renal disease, (aspartate aminotransferase (AST) or alanine transaminase (ALT) \> 3x ULN or Total bilirubin \> 3 x ULN), (CrCl \< 60 ml/min (based on the Cockroft-Gault equation)
• • Neoplasm, or hematological disorders
• • Pregnant or breast-feeding patients
• • Active participation in another clinical study
• • Patients taking antioxidant drugs.
• • History of or known allergy or intolerability to the study medications